WCN26-4054 CLINICAL RESPONSE TO LUMASIRAN IN A PH1 PATIENT ON HEMODIALYSIS: CHALLENGES IN OXALATE CONTROL UNDER LIMITED DIALYSIS ACCESS

Read full text Summarise with VIRAT
Authors: Christine Zomer Dal Molin, Andreia Batista Bialeski
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder caused by mutations in the AGXT gene, leading to excessive hepatic oxalate production and progressive kidney damage. Calcium oxalate accumulation results in nephrocalcinosis, urolithiasis, and systemic oxalosis, especially after renal function declines. Traditional treatments include hyperhydration, citrate, and pyridoxine, which is effective in select genotypes. However, many patients progress to end-stage kidney disease (ESKD), particularly in settings with delayed diagnosis.

Fields of Study & Subjects

Kidney Stones and Urolithiasis Treatments Parathyroid Disorders and Treatments Metabolism and Genetic Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106008–106008
Publication date
25 March 2026
Language
EN